If Esperion Wants To Market The Next Big Cholesterol Drug, It Will Take Strategy

After updating investors this week on its strategy for tackling the blockbuster market for cholesterol lowering drugs, shares in Esperion Therapeutics (NASDAQ:ESPR) are rocketing higher.

Here’s how the company plans to make its cholesterol-lowering drug, bempedoic acid, a commercial success someday.